Vertex's VX880 Trial Shows Sustained Insulin Independence in 10 Patients

New data from Vertex's ongoing study reveals that 10 of 12 patients with Type 1 diabetes remained insulin-independent for a full year after receiving VX880 therapy. The results come with an important trade-off: all participants require immunosuppressive medications to maintain the benefit.

cure researchbeta cellsadvancements

Key takeaways

In a subset of 12 patients from Vertex's 50-person VX880 trial, 10 achieved insulin independence lasting at least one year
Two additional patients became partial responders, producing some of their own insulin while improving time-in-range and A1C levels
All participants taking VX880 require ongoing immunosuppressive drugs, which carry their own side effects and reduce immune function
This is an experimental therapy still in clinical trials, not an approved treatment

What Happened in This Trial

Vertex Pharmaceuticals released updated results from their VX880 clinical trial, focusing on outcomes in 12 of the trial's 50 total participants. The most striking finding: 10 of these 12 patients no longer required insulin injections or pumps and maintained this insulin independence for a full year or longer.

Two other patients in this group did not achieve complete insulin independence but showed meaningful improvement. They began producing some of their own insulin and achieved time-in-range readings of 70% or higher, with A1C levels dropping below 7%.

The Immunosuppression Requirement

A critical detail: every patient in this trial requires ongoing immunosuppressive medications to maintain these results. These drugs work by dampening the immune system's activity, which allows the transplanted cells in VX880 therapy to function without being attacked by the body.

Immunosuppressive medications come with real trade-offs. People taking them have a weaker immune response, which increases their vulnerability to infections and other illnesses. This means the benefit of insulin independence must be weighed carefully against these medical risks.

What This Means Right Now

These results represent important progress in Type 1 diabetes research and offer hope for future treatments. However, VX880 remains an experimental therapy under investigation—it is not yet approved for use outside of clinical trials.

The data shows what is possible with current technology, but also highlights the ongoing challenge: finding ways to achieve lasting benefit without requiring lifelong immunosuppression. Researchers continue working toward that goal.

Evidence label

Origin: YouTube / Diabetech (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.